Introduction {#s1}
============

Synonymous mutations in protein-coding genes preserve an encoded amino acid (AA), and so by Anfinsen's principle [@pone.0095034-Anfinsen1], should not affect the protein product. Presumably having no fitness effect, synonymous mutations therefore should be invisible to natural selection. However, it has long been suggested that translational selection on synonymous codon usage may act to adapt to organism's tRNA pools [@pone.0095034-Clarke1], [@pone.0095034-Ikemura1]. In many genes and organisms, differences in abundance of cognate tRNAs for different synonymous codons lead to selection pressure to maximize translation rate in favor of codons that that are read by the most abundant tRNA [@pone.0095034-Akashi1], [@pone.0095034-Duret1], [@pone.0095034-Wright1]. Therefore, the key signature of translational selection is the codon bias in favor of optimal codons affecting whole genes, where fast accurate translation ensures high levels of expression. More recently, experimental studies showed that rare codons may also be favored and selection could act differentially at different synonymous sites, even within the same gene. For example, rare codons may be more frequent in genes with low level of expression, if slow translation is more favorable [@pone.0095034-Gingold1], or involved in regulating expression levels over the time course [@pone.0095034-FrenkelMorgenstern1]. Overall, several stages prior to translation involved in protein production may be sensitive to codon choice [@pone.0095034-Chamary1]. Today overwhelming evidences indicate that synonymous mutations can be under site-specific selection on synonymous codon choice. Synonymous mutations can affect splicing control elements, such as exonic splicing enhancers and silencers [@pone.0095034-Fairbrother1], [@pone.0095034-Wang1] and even can create new 'cryptic' splice sites [@pone.0095034-Eskesen1], and so will be affected by selection to avoid codons that could be incorrectly identified as intronic ends. To ensure correct splicing, selection may constrain the synonymous rates of evolution in domains associated with splice control [@pone.0095034-Hurst1], [@pone.0095034-Orban1] and in alternatively spliced exons [@pone.0095034-Iida1], [@pone.0095034-Lu1], [@pone.0095034-Xing1]. Constraints on synonymous changes help to ensure efficient binding of microRNA to sense mRNA as a mode of gene regulation [@pone.0095034-Chamary1]. Plenty of studies indicate that synonymous mutations can have direct effect on mRNA structure stability, often causing drastic phenotypic effect [@pone.0095034-Duan1], [@pone.0095034-Nackley1], [@pone.0095034-Capon1]. Perhaps even more surprisingly, synonymous mutations can affect the protein folding. Kimchi-Sarfaty and colleagues [@pone.0095034-KimchiSarfaty1] demonstrated that a synonymous change in the multidrug resistance-1 gene (MDR-1) causes protein misfolding. The protein with the new altered form helps the cancer cells to get rid of the chemotherapy drug much more efficiently, making the drug useless [@pone.0095034-KimchiSarfaty1]. Indeed, the folding of a peptide chain is somewhat speed-dependent, and slower production influences the final 3D form of the protein product. Translational pausing due to the usage of rare codons explains why stretches of rare codons were found to correlate to turns, loops and links between protein domains [@pone.0095034-Thanaraj1], [@pone.0095034-Oresic1].

In sum, it is now evident that synonymous mutations can be under a variety of selective mechanisms. With over 40 genetic diseases (including cancers and diabetes) associated with synonymous mutations, it is now clear that such mutations can have important fitness consequences, unlike previously thought [@pone.0095034-Sauna1], [@pone.0095034-Sauna2]. Chamary and Hurst [@pone.0095034-Chamary2] estimated that 5--10% of human genes contain at least one region where silent mutations could be harmful. Based on the analysis of human genetic associations of SNPs with disease, Chen et al. [@pone.0095034-Chen1] concluded that non-synonymous and synonymous SNPs show similar likelihood and effect size of human disease association. Finally, synonymous mutations may be responsible for individual differences in disease susceptibility and treatment outcomes (see [@pone.0095034-Sauna2] for a comprehensive review).

Recently, many large-scale statistical studies focused on detecting pervasive positive diversifying selection on the protein, as measured by the nonsynonymous to synonymous rates ratio *ω* = *d~N~*/*d~S~* [@pone.0095034-Anisimova1]. However, patterns of selection on synonymous codons are poorly understood. Most often negative selection on synonymous codons is studied by measuring the average codon usage per gene. Resch et al. [@pone.0095034-Resch1] performed a large-scale scan for positive selection on synonymous sites, where average pairwise synonymous substitution rate *d~S~* for a gene was compared to the corresponding average intron rate in mouse-rat gene pairs. This approach found that positive selection on synonymous sites could be even more frequent than positive selection on the protein. However, the pairwise averaging approach typically lacks power [@pone.0095034-Yang1] and overlooks the impact of site-specific synonymous rate variation (SRV) over the protein-coding sequence. Zhou et al. [@pone.0095034-Zhou1] proposed to distinguish synonymous rates of change between different types of synonymous codons ("preferred" and "un-preferred"). Applied to yeast and worm genes, their method found substantially lower number of genes with positive selection on synonymous sites compared to [@pone.0095034-Resch1]. Clearly, the accuracy of such an approach would be affected by uncertainties in identifying preferred and un-preferred codons. But perhaps more importantly, the method of Zhou et al. [@pone.0095034-Zhou1] models only average synonymous rates per gene and so cannot capture site-specific selection pressure that acts on the DNA or mRNA level related to transcription, splicing, expression regulation or mRNA structure stability. Significant variation of synonymous rates (*d~S~*) reflects that the evolutionary forces act differently at different synonymous sites, likely due to variation in selective constraints. Thus candidate genes affected by either purifying or positive selection on the DNA can be detected with a systematic analysis of the SRV, using the extent of *d~S~* variation as a proxy for selection.

Here for the first time we present a large-scale analysis of homologous proteins -- with the aim to improve our understanding of the nature of synonymous changes and the SRV in protein-coding sequences. In contrast to the study of Resch et al. [@pone.0095034-Resch1], we analyzed multiple sequence alignments (where evolutionary information is at the maximum) using Markov codon models with SRV. We determined how often and where strong SRV occurs, and listed the gene properties that make the SRV more likely. The patterns of SRV and groups of genes enriched with SRV may provide important clues for other studies focusing on understanding disease, optimizing transgene design, as well as those dedicated to determining specific and general evolutionary trends in molecular sequences. Our study opens directions for exploring new measures of selective pressure that incorporate the effect of selection on synonymous sites.

Materials and Methods {#s2}
=====================

The Data {#s2a}
--------

7738 homologous groups and corresponding alignments of protein-coding DNA and AA sequences were obtained from the PANDIT database v17.0 [@pone.0095034-Whelan1]; <http://www.ebi.ac.uk/goldman-srv/pandit>). PANDIT contains protein domains and families, derived from the Pfam-A seed alignments [@pone.0095034-Punta1]. Phylogenetic trees were inferred for each homologous group by maximum likelihood (ML) under the amino acid model LG+Γ+F, as implemented in PhyML3.0 [@pone.0095034-Guindon1]. These ML estimates of trees were consequently used for all optimizations under codon models (see below). To avoid drawing conclusions based on saturated alignments, we removed groups where the average divergence was greater than two expected substitutions per amino acid site per branch ([Figure S1](#pone.0095034.s001){ref-type="supplementary-material"}). Annotations for each homologous group were taken from the PANDITplus database [@pone.0095034-Dimitrieva1]; <http://panditplus.org>), an extension of PANDIT, integrating data from a variety of reliable and curated bioinformatics sources. It provides access to data on protein interactions, functional and chemical pathway annotation, gene expression and association with diseases. The estimates from evolutionary codon models computed for this study are now also available from PANDITplus.

Analyses of Positive Selection (PS) on the Protein and the Synonymous Rate Variation (SRV) {#s2b}
------------------------------------------------------------------------------------------

Pervasive diversifying positive selection (PS) on the protein was evaluated by ML using Markov models of codon evolution, as implemented in the codeml program from the PAML package v4.1 [@pone.0095034-Yang2]. The selective pressure at the protein level was measured by the *ω*-ratio, with *ω*\<1,  = 1, or \>1 indicating purifying, neutral or positive selection on the protein respectively [@pone.0095034-Yang3]. For each homologous group we computed estimates of the average *ω* using model M0, which assumes constant selective pressure across codon sites and over time. ML estimates of branch lengths under M0 were then used as starting (or fixed) values in all following computations under codon models. Likelihood ratio test (LRTs) of nested codon models M0 vs M3, and M7 vs M8 was used to determine whether a gene was affected by selection [@pone.0095034-Anisimova2], [@pone.0095034-Anisimova3], [@pone.0095034-Wong1]. Evidence for adaptive evolution in a gene was considered sufficient if the following conditions were met: (1) both LRTs were significant at 5% level with an estimated ω\>1, (2) the estimated proportion of positively selected sites was large enough to include at least one site, and (3) the SRV-aware model (DUAL, [@pone.0095034-Pond1]) supported the presence of PS. Condition (3) was required to avoid a potential bias on the detection of PS as a result of SRV. Groups of proteins with evidence of PS are further refereed to as PS+, while those with no such evidence are denoted as PS−.

To determine whether a gene exhibited site-to-site SRV, we applied an LRT between a codon model where *d~S~* was assumed constant (model M3) and a model where both *d~S~* and *d~N~* could vary (DUAL model) [@pone.0095034-Pond1]. ML optimization for this task was performed with the HYPHY program [@pone.0095034-Pond1]. Both *d~S~* and *d~N~* were assumed to be drawn from independent general discrete distributions, each with three rate categories. Evidence for site-to-site SRV was considered sufficient if: (1) the LRT was significant at 5% level and (2) the coefficient of variation (CV) of the synonymous rates was \>0. The second condition was added to exclude the few cases with artifacts of ML estimation, where the LRT showed significantly better fit of the model with variable *d~S~*, but yet the estimated CV of *d~S~* was 0. Data classified as having significant SRV is further referred to as SRV+ set, while data where *d~S~* can be assumed constant is further referred to as SRV−.

Patterns in 7341 data sets were analyzed, after filtering out protein groups that were too diverged or had convergence problems during ML optimizations. To avoid optimization problems each analysis was performed multiple times and one with a higher log-likelihood was selected.

Analyses of Over/Under-representation in Functional Categories {#s2c}
--------------------------------------------------------------

GO and KEGG annotations for each group were obtained from PANDITplus [@pone.0095034-Dimitrieva1]. To account for the hierarchical nature of GO and KEGG data, each gene (protein) was considered to belong to all parent categories where it was directly assigned. To test the over/under-representation of genes with specific feature (PS or SRV), the data sets were divided into two groups: those showing evidence for the feature of interest (PS+, SRV+) and those that failed to show such evidence (PS−, SRV−). For each tested functional category *C*, a 2×2 contingency table was constructed containing the numbers of genes assigned and not assigned to *C.* To test for independence of rows and columns one-sided *P*-values were computed using Fisher's exact test. As test sets overlapped, the raw *P*-values from Fisher's exact test were adjusted to control the false discovery rates [@pone.0095034-Benjamini1].

Codon Bias, Autocorrelation and Nucleotide Composition {#s2d}
------------------------------------------------------

For each protein group, we computed total GC content, GC content at third codon positions (GC3), and codon usage indices CBI (Codon Bias Index, [@pone.0095034-Bennetzen1]) and ENC (Effective Number of Codons, [@pone.0095034-Wright2]), using the CodonW program [@pone.0095034-Peden1]. CBI measures the usage of optimal codons, ranging between 1 (only optimal codons are used) to −1 (only non-optimal codons are used), with 0 for random codon choice. ENC is another measure of synonymous codon usage, ranging between 20 (only one codon is used for each AA) and 61 (codons are used randomly).

Finally, we computed the TPI (tRNA Pairing Index), a statistical measure of tRNA reusage [@pone.0095034-Friberg1], [@pone.0095034-Cannarozzi1], using the dedicated Darwin functions [@pone.0095034-Gonnet1]. By definition, the TPI ranges from −1 for perfectly anticorrelated tRNA changes (i.e maximal number of tRNA changes) to +1 for perfectly autocorrelated (minimal number of tRNA changes). For example, in a sequence where one AA is encoded by two tRNAs X and Y, highly autocorrelated case is XXXXYYYY, while XYXYXY is highly anticorrelated case. For a comprehensive review of codon usage measures see [@pone.0095034-Roth1].

Note that when measuring the correlation between any two phenomena, we computed both Spearman and Pearson correlation coefficients, which provided very similar results. We therefore show only the Spearman correlation values.

Analyses of Gene Expression Data {#s2e}
--------------------------------

Several sources of gene expression data were used in this study. Mappings of gene expression in human tissues (data from HumanProteinpedia [@pone.0095034-Kandasamy1]) were obtained from PANDITplus. These data do not contain information on the expression levels, but only inform whether a gene is expressed in a certain human tissue or not. Fisher's exact tests were performed to identify the tissues with over/under-representation of expressed genes with SRV and PS. Information on human gene expression breadth of Ensembl genes from three types of experiments (Gene Atlas microarray, EST and SAGE) was taken from [@pone.0095034-Necsulea1]. These data provide information on the gene expression breadth measured by the number of tissues where the gene is expressed, but no information about the expression levels or the tissue of expression. Ensembl gene IDs were mapped to Pfam IDs using BioMart module of the Ensembl database v.62 [@pone.0095034-Flicek1]. Note that in the expression data analyses we used gene-Pfam mappings derived from gene associations with full Pfam alignments. We also analyzed expression data from Gene Atlas U133A Affymetrix microarray from the BioGPS portal of the Genomics Institute of the Novartis Research Foundation ([@pone.0095034-Su1]; <http://biogps.gnf.org/downloads>), mapping individual protein sequences from the seed PANDIT alignments to microarray probes. We used these data to analyze gene expression levels by calculating the distribution of the log expression values for the categories of interests.

Clustering Analyses {#s2f}
-------------------

Hierarchical clustering of gene categories was performed for KEGG pathways. The dissimilarity matrix for the clustering was defined so that any two categories A and B from the same hierarchical level had dissimilarity *d* ~AB~ = 0 when all SRV+ genes were assigned to both categories A and B, and dissimilarity *d* ~AB~ = 1 when A and B did not share any SRV+ gene. More specifically, dissimilarity between two categories A and B was defined as:where N(X) denotes the number of SRV+ genes in category X.

Results {#s3}
=======

Significant SRV was found in 42% (or 37%) of protein groups at 5% (or 1%) significance level. This suggests that the phenomenon of site-to-site heterogeneity of synonymous rates is widespread and deserves attention. Extreme SRV was detected in 154 datasets (CV≥1, see [Table S1](#pone.0095034.s010){ref-type="supplementary-material"}). Notably, certain Pfam clans were exclusively composed of SRV+ groups. Recall that clans are higher-level clusters of related families, grouped based on structure, function, matching of families HMMs and profile-profile comparisons. The list of SRV exclusive clans includes p53-related proteins and ABC transporters (see [Table S2](#pone.0095034.s011){ref-type="supplementary-material"}).

Note that PS on the protein was detected in 11% (or 7%) of groups at 5% (or 1%) significance level (consistent with previous estimates, eg. [@pone.0095034-ArisBrosou1]). We observed weak but significant negative correlation (*ρ* = −0.11, *P*\<10^−16^) between the variability of synonymous rates and the average *ω*-ratio across protein sites. This indicates that proteins that are more conserved tend to have greater SRV among sites. A bootstrap analysis on the differences in mean *ω* for protein groups classified as SRV+ and SRV−, confirmed that proteins with SRV tend to be under stronger purifying selection (lower *ω*) compared to proteins where synonymous rates may be assumed constant ([Figure 1A](#pone-0095034-g001){ref-type="fig"}).

![Bootstrap distribution of the differences in A) the mean ω-ratio, B) tRNA reusage, measured through tRNA Pairing Index (TPI), C) number of interactions and D) number of structures, between protein groups having site-to-site variation in synonymous rates (SRV+) and protein groups having constant synonymous rates (SRV−).\
The plots B), C) and D) also show the bootstrap distributions of the corresponding differences between protein groups showing evidence for positive selection (PS+) and those failing to show such evidence (PS−). All differences (except for TPI in PS+/PS− data) are significant since 95% of the histogram area does not include the zero value.](pone.0095034.g001){#pone-0095034-g001}

Reflecting Pfam, our protein groups included protein families (74%), domains (23%), motifs (1%) and repeats (2%). SRV was significantly overrepresented in protein domains, but underrepresented in protein families ([Table 1](#pone-0095034-t001){ref-type="table"}). An opposite pattern was observed for PS: protein domains showed significant underrepresentation of groups with PS, while protein families were overrepresented with PS+ groups. Motifs and repeats did not show any significance for over or underrepresentation with SRV+ or PS+ groups, most likely due to their small dataset numbers and short sequences, which increased variance of ML estimates.

10.1371/journal.pone.0095034.t001

###### Overrepresentation (+) and underrepresentation (−) of SRV and PS in different data categories.

![](pone.0095034.t001){#pone-0095034-t001-1}

  Pfam type            SRV      PS             
  ------------------ ------- --------- ------- ---------
  Protein Domains     **+**   10^−33^     −     10^−9^
  Protein Families      −     10^−28^   **+**   10^−10^

Dependencies between Site-to-site SRV and Gene Properties {#s3a}
---------------------------------------------------------

Selection for translational speed favors codons matching the cognate tRNA profile. We investigated whether the codon bias and tRNA reusage could contribute to the observed site-to-site SRV. CV of synonymous rates was correlated with both codon bias and tRNA reusage ([Table S3](#pone.0095034.s012){ref-type="supplementary-material"}). In the SRV+ group the average codon bias and tRNA reusage were significantly larger than in the SRV− group ([Figure 1B](#pone-0095034-g001){ref-type="fig"}; [Figure S2](#pone.0095034.s002){ref-type="supplementary-material"}, [Table 2](#pone-0095034-t002){ref-type="table"}). In contrast PS+ group had on average weaker codon bias compared to the PS− group ([Table 2](#pone-0095034-t002){ref-type="table"}, [Figure S2](#pone.0095034.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0095034.t002

###### Differences between the mean values of the attribute (\#interactions, \#structures, codon bias and tRNA reusage) in SRV+ and SRV− data, and in PS+ and PS− data correspondingly.

![](pone.0095034.t002){#pone-0095034-t002-2}

  Attribute                       Difference between attribute means in SRV+ and SRV− data (median \[IQR\])   Difference between attribute means in PS+ and PS− data (median \[IQR\])
  ------------------------------ --------------------------------------------------------------------------- -------------------------------------------------------------------------
  **Interactions**                                            0.50 \[0.48, 0.53                                                       −0.42 \[−0.44, −0.39\]
  **Structures**                                           17.72 \[16.65, 18.80\]                                                    −11.38 \[−10.12, −12.59\]
  **Codon bias (CBI measure)**                              0.02 \[0.019; 0.022\]                                                    −0.01 \[−0.018; −0.011\]
  **Codon bias (ENC measure)**                              −1.3 \[−1.39; −1.22\]                                                       1.0 \[0.84; 1.18\]
  **tRNA reusage**                                           0.14 \[0.13; 0.15\]                                                      −0.01 \[−0.02; 0.005\]
  **GC content**                                            0.042 \[0.04; 0.043\]                                                    −0.041 \[−0.038; −0.043\]
  **GC3 content**                                          0.08 \[0.078; 0.083\],                                                    −0.08 \[−0.085; −0.076\]

All p-values are \<10^−16^, except for the differences in mean values of tRNA reusage (TPI) between PS+/PS− data where there was no significance. This table corresponds to [Figure 1](#pone-0095034-g001){ref-type="fig"} and [Figure S2](#pone.0095034.s002){ref-type="supplementary-material"}.

It has been suggested that selection at synonymous sites favors high GC, which is reflected in a correlation between codon bias and GC3, the GC content at third codon positions [@pone.0095034-Chamary3]. Some studies reported that GC at synonymous sites was higher than in the flanking introns [@pone.0095034-EyreWalker1], [@pone.0095034-Hughes1], and that GC content could contribute to the regulation of splicing signals, in which case synonymous mutations may lead to exon skipping associated with disease [@pone.0095034-Amit1]. These evidences indicate the possibility of selection acting on synonymous sites. In our data we observed that the variability of *d~S~* correlated positively with the variation of GC and GC3 among homologous genes, but not very well with the GC and GC3 content (see also [Figure S3](#pone.0095034.s003){ref-type="supplementary-material"} and [Table S3](#pone.0095034.s012){ref-type="supplementary-material"}).

Our results suggest that proteins with many interactions evolved under stricter purifying selection ([Figure 1C](#pone-0095034-g001){ref-type="fig"}), which is in agreement with the extended complexity hypothesis [@pone.0095034-ArisBrosou1]. We observed positive correlation between the number of interactions and CV of *d~S~* (*ρ* = 0.22, *P*\<10^−16^; [Figure 1C](#pone-0095034-g001){ref-type="fig"}). Since SRV and PS groups were unequally represented within different data types (domains, families, motifs and repeats), bootstrap analyses were repeated for each data type separately. The reported trends were significant for domains, families and repeats. Further, proteins forming many structural complexes exhibited stronger SRV ([Figure 1D](#pone-0095034-g001){ref-type="fig"}) and tended to be more conserved and less likely to be under recurrent diversifying positive selection. We observed positive correlation between the number of structural complexes that proteins can form and the CV of *d~S~* (*ρ* = 0.22, *P*\<10^−16^), and weak negative correlation with the *ω*-ratio (*ρ* ~Spearman~ = −0.08, P\<10^−12^; Pearson correlation was not significant).

Overall, our data show that there is a correlation between the individual variables, most notable between GC and GC3 content (*ρ* = 0.92); codon bias and GC3 content (*ρ* = 0.74); codon bias and GC content (*ρ* = 0.73); number of interactions and number of structures (*ρ* = 0.52); codon bias and codon autocorrelation (*ρ* = 0.41); GC content and codon autocorrelation (*ρ* = 0.23) etc. However, some of these variables could be independently associated with one another. For instance, it has been widely reported that codon bias is associated with various biological factors, such as gene expression level, tRNA abundance, GC composition, protein structure etc. Furthermore, it was shown that the similarity in codon usage is a strong predictor of protein-protein interactions [@pone.0095034-Najafabadi1]. To get more insights, we conducted a multivariate analysis and sought to find the individual variables that give the greatest separations between the SRV+ and SRV− groups. We quantified the "separation" F between the SRV+ and SRV− groups achieved by a particular variable (*ω*-ratio, CBI, TPI, GC/GC3 content, \#interactions, \#structures) as the ratio of its "between-groups" variance to its "within-groups" variance. Surprisingly, the greatest separation between the two groups was achieved based on the number of protein-protein interactions (F = 218), followed by the tRNA reusage index (F = 193), the number of protein structures (F = 146), the *ω*-ratio (F = 74), codon bias (F = 68), GC3 content (F = 30) and GC content (F = 16). Finally, we performed principal component analysis (PCA) to investigate whether most of the variation between our SRV+/SRV− data can be captured using principal components that were linear combinations of all or some of the other variables (*ω*-ratio, CBI, TPI, GC/GC3 content, \#interactions, \#structures). The first two principal components (PC) explain 70% of the variance of SRV. The first PC (explaining 45% of the variance) represented a contrast between the *ω*-ratio and the other variables (CBI, TPI, GC content, GC3 content, \#interactions, \#structures), with the largest loadings (in absolute) values for GC3 content (0.59), GC content (0.59) and CBI (0.55), the loadings of the other components were \<0.06. This supports the negative correlation between CV of SRV and the *ω*-ratio, and its positive correlation with all the other variables, but suggests that omega has little impact (based on the low loading value). The second PC represents a contrast between the *ω*-ratio, CBI, TPI, \#interactions and \#structures, and the variables GC content and GC3 content. The largest loadings of this PC were for \#interactions (0.7), \#structures (0.7), while the loadings (in absolute) values of the other variables were \<0.08. Overall, the PCA demonstrates that the influence of the above-mentioned factors on SRV is complex due to the strong dependencies among them.

Site-to-site SRV and Protein Function, Interactions and Reaction Networks {#s3b}
-------------------------------------------------------------------------

We examined the distribution of GO functional categories [@pone.0095034-Ashburner1] with respect to site-to-site SRV. Since our protein groups were unevenly distributed among GO categories ([Figure S4](#pone.0095034.s004){ref-type="supplementary-material"}), significant over/under-representation was more difficult to detect for sparsely sampled categories, with better power for GO terms annotating larger number of protein groups.

[Table 3](#pone-0095034-t003){ref-type="table"} summarizes the results of GO-enrichment tests for "Cellular Component". Categories enriched with SRV+ proteins included cell envelope, membrane, wall and external encapsulating structure. Underrepresentation of SRV+ proteins was found in extracellular region, membrane-enclosed lumen and organelles. Our results for PS+ proteins are consistent with previous findings [@pone.0095034-ArisBrosou1], [@pone.0095034-Kosiol1]: extracellular region and MHC protein complex were found as overrepresented with PS+ proteins, while the cellular components that are mostly internal to the cell, organelles and macromolecular complex were identified as strongly conserved.

10.1371/journal.pone.0095034.t003

###### Over/under-representation of selective forces in GO categories for Cellular Component.

![](pone.0095034.t003){#pone-0095034-t003-3}

  GO Categories                                    *SRV*      *PS*      \#pfam               
  ----------------------------------------------- ------- ------------ -------- ------------ ----------
  **cellular component**                                                                     
  * extracellular region*                          **−**   **\*\*\***   **+**    **\*\*\***   **205**
  ** cell**                                        **+**    **\*\***    **−**     **\*\***    **1491**
  **  cell part**                                  **+**    **\*\***    **−**     **\*\***    **1491**
    intracellular                                                       **−**     **\*\***      872
  **   membrane**                                  **+**     **\***                           **717**
  **   cell wall**                                 **+**     **\***                            **29**
  **   cell envelope**                             **+**    **\*\***                           **38**
  *   endomembrane system*                         **−**    **\*\***                           **55**
  **   external encapsulating structure**          **+**    **\*\***                           **63**
    intracellular part                                                  **−**     **\*\***      773
  **     extrachromosomal DNA**                    **+**    **\*\***                           **6**
  **     ribonucleoprotein complex**               **+**     **\***                           **116**
  virion                                                                **+**    **\*\*\***     151
   virion part                                                          **+**     **\*\***      141
    viral capsid                                                        **+**      **\***        98
    viral envelope                                                      **+**      **\***        35
  * membrane-enclosed lumen*                       **−**    **\*\***                           **25**
  *  organelle lumen*                              **−**    **\*\***                           **23**
  *   intracellular organelle lumen*               **−**    **\*\***                           **23**
  macromolecular complex                                                **−**      **\***       346
    ribosome                                                            **−**     **\*\***       98
    MHC protein complex                                                   \+        \*\*         4
  * organelle*                                     **−**   **\*\*\***   **−**     **\*\***    **597**
  *  membrane-bounded organelle*                   **−**   **\*\*\***   **−**      **\***     **423**
  *   intracellular membrane-bounded organelle*    **−**   **\*\*\***   **−**      **\***     **420**
  *  intracellular organelle*                      **−**   **\*\*\***   **−**     **\*\***    **593**

Notation: Significance levels are at the 5% (\*), 1% (\*\*), or 0.1% (\*\*\*). Boldface indicates overrepresentation of SRV; italics indicates underrepresentation of SRV.

Analyses of "Molecular function" categories are summarized in [Table 4](#pone-0095034-t004){ref-type="table"}. Categories enriched with SRV+ proteins included catalytic and transporter proteins, proteins with a role in carrying electrons, or those important for binding (with exception of receptor binding). Underrepresentation of SRV+ proteins was observed among the proteins that participate in receptor binding and enzyme regulation. Categories underrepresented with PS+ proteins included catalytic and transporter proteins, and those with a role in binding.

10.1371/journal.pone.0095034.t004

###### Over/under-representation of selective forces in GO categories for Molecular Function.

![](pone.0095034.t004){#pone-0095034-t004-4}

  GO Categories                                             *SRV*      *PS*      \#pfam               
  -------------------------------------------------------- ------- ------------ -------- ------------ ----------
  **molecular function**                                                                              
  ** electron carrier activity**                            **+**     **\***                            **53**
  ** catalytic activity**                                   **+**   **\*\*\***   **−**    **\*\*\***   **1536**
  **  oxidoreductase activity**                             **+**    **\*\***    **−**    **\*\*\***   **251**
   transferase activity                                     **+**     **\***     **−**      **\***       444
    transferase activity, transferring one-carbon groups                         **−**     **\*\***       76
  **  hydrolase activity**                                  **+**   **\*\*\***                         **533**
  **  isomerase activity**                                  **+**   **\*\*\***                          **58**
  **  ligase activity**                                     **+**   **\*\*\***                          **75**
  **   ligase activity, forming carbon-oxygen bonds**       **+**   **\*\*\***                          **25**
  structural molecule activity                                                                           220
   structural constituent of ribosome                                            **−**     **\*\***       98
  ** transporter activity**                                 **+**    **\*\***    **−**      **\***     **221**
  ** binding**                                              **+**   **\*\*\***   **−**    **\*\*\***   **1286**
  **  nucleotide binding**                                  **+**   **\*\*\***   **−**     **\*\***    **263**
  **   purine nucleotide binding**                          **+**   **\*\*\***   **−**      **\***     **231**
  **   ribonucleotide binding**                             **+**   **\*\*\***   **−**      **\***     **217**
   protein binding                                                               **−**      **\***     **244**
  *   receptor binding*                                     **−**     **\***                            **83**
  **  nucleoside binding**                                  **+**   **\*\*\***   **−**      **\***     **200**
  **   purine nucleoside binding**                          **+**   **\*\*\***   **−**      **\***     **199**
  **  nucleic acid binding**                                **+**    **\*\***    **−**    **\*\*\***   **515**
    DNA binding                                                                  **−**     **\*\***      368
  **  carbohydrate binding**                                **+**     **\***                            **27**
   ion binding                                                                   **−**     **\*\***      270
    cation binding                                                               **−**     **\*\***      269
  **  cofactor binding**                                    **+**   **\*\*\***                          **61**
  **  coenzyme binding**                                    **+**   **\*\*\***                          **47**
  * enzyme regulator activity*                              **−**    **\*\***                           **68**

Notation: Significance levels are at the 5% (\*), 1% (\*\*), or 0.1% (\*\*\*). Boldface indicates overrepresentation of SRV; italics indicates underrepresentation of SRV.

Enrichment analyses of "Biological process" categories are summarized in [Table 5](#pone-0095034-t005){ref-type="table"}. We found an overrepresentation of SRV+ among the proteins with function in metabolism, cellular processes and in localization and transport. Proteins that participate in multi-organism processes (symbiosis, interaction with host), defensive response to stimulus and reproduction were found as least likely to have significant site-to-site SRV. For PS+ proteins we observed the opposite: proteins involved in metabolic and cellular processes, as well as biological regulation were found to be most conserved and least likely to undergo adaptive evolution. Proteins related to immune system processes and response to stimulus, which represent obvious targets for adaptive evolution, were enriched with PS.

10.1371/journal.pone.0095034.t005

###### Over/under-representation of selective forces in GO categories for Biological Processes.
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  GO Categories                                                   *SRV*      *PS*      \#pfam               
  -------------------------------------------------------------- ------- ------------ -------- ------------ ----------
  **biological process**                                                                                    
  * reproduction*                                                 **−**    **\*\***    **+**      **\***     **130**
  ** metabolic process**                                          **+**   **\*\*\***   **−**    **\*\*\***   **1807**
   oxidation reduction                                                                 **−**     **\*\***       98
  **  nitrogen compound metabolic process**                       **+**   **\*\*\***   **−**    **\*\*\***   **883**
  **   amine metabolic process**                                  **+**   **\*\*\***   **−**      **\***     **127**
  **   cellular nitrogen compound metabolic process**             **+**     **\***     **−**    **\*\*\***   **840**
  **  biosynthetic process**                                      **+**   **\*\*\***   **−**    **\*\*\***   **879**
  **   macromolecule biosynthetic process**                       **+**     **\***     **−**    **\*\*\***   **591**
    regulation of biosynthetic process                                                 **−**     **\*\***      231
  **   cellular biosynthetic process**                            **+**    **\*\***    **−**    **\*\*\***   **838**
   regulation of metabolic process                                                     **−**     **\*\***      260
  **  macromolecule metabolic process**                           **+**   **\*\*\***   **−**    **\*\*\***   **1022**
  **   gene expression**                                          **+**   **\*\*\***   **−**    **\*\*\***    **62**
  **   macromolecule biosynthetic process**                       **+**   **\*\*\***   **−**    **\*\*\***   **591**
  **   protein metabolic process**                                **+**   **\*\*\***   **−**    **\*\*\***   **378**
  **   cellular macromolecule metabolic process**                 **+**   **\*\*\***   **−**    **\*\*\***   **875**
  **  cellular metabolic process**                                **+**   **\*\*\***   **−**    **\*\*\***   **1383**
  **   organic acid metabolic process**                           **+**   **\*\*\***                         **139**
  **   cellular amino acid and derivative metabolic process**     **+**   **\*\*\***   **−**      **\***     **113**
  **   cellular nitrogen compound metabolic process**             **+**    **\*\***    **−**    **\*\*\***   **840**
  **   cellular ketone metabolic process**                        **+**   **\*\*\***   **−**     **\*\***    **139**
  **   cellular biosynthetic process**                            **+**   **\*\*\***   **−**    **\*\*\***   **838**
  **   cellular macromolecule metabolic process**                 **+**   **\*\*\***   **−**    **\*\*\***   **875**
  **   cellular carbohydrate metabolic process**                  **+**   **\*\*\***                         **102**
  **  primary metabolic process**                                 **+**   **\*\*\***   **−**    **\*\*\***   **1409**
  **   carbohydrate metabolic process**                           **+**   **\*\*\***                         **228**
    nucleobase, nucleoside, nucleotide and nucl. acid m. proc.                         **−**    **\*\*\***     696
  **   cellular amino acid and derivative metabolic process**     **+**   **\*\*\***   **−**      **\***     **113**
  **   protein metabolic process**                                **+**   **\*\*\***   **−**    **\*\*\***   **378**
  **  small molecule metabolic process**                          **+**   **\*\*\***   **−**      **\***     **349**
  **   alcohol metabolic process**                                **+**    **\*\***                           **64**
  **   organic acid metabolic process**                           **+**   **\*\*\***                         **139**
  **   cellular amino acid and derivative metabolic process**     **+**   **\*\*\***   **−**      **\***     **113**
  **   cellular ketone metabolic process**                        **+**   **\*\*\***   **−**     **\*\***    **139**
  immune system process                                                                **+**     **\*\***       27
   immune response                                                                     **+**    **\*\*\***      26
  *  antigen processing and presentation*                                               *+*       *\*\**       *4*
  ** viral reproduction**                                                                                    **123**
   viral reproductive process                                                                               
    viral assembly, maturation, egress, and release                                    **+**      **\***        25
    virion assembly                                                                    **+**      **\***        20
  *   viral capsid assembly*                                                            *+*        *\**        *10*
  ** cellular process**                                           **+**   **\*\*\***   **−**    **\*\*\***   **1782**
  *  cell communication*                                          **−**     **\***                            **35**
  **  cellular metabolic process**                                **+**   **\*\*\***   **−**    **\*\*\***   **1383**
   regulation of cellular process                                                      **−**     **\*\***      332
   cellular localization                                                               **−**    **\*\*\***      85
  developmental process                                                                **+**      **\***        89
  response to stimulus                                                                 **+**     **\*\***      202
   response to stress                                                                  **+**      **\***       132
  *   defense response*                                           **−**    **\*\***    **+**    **\*\*\***    **36**
    response to wounding                                                                *+*       *\*\**       *9*
   immune response                                                                     **+**    **\*\*\***      26
  ** localization**                                               **+**   **\*\*\***   **−**     **\*\***    **360**
   macromolecule localization                                                          **−**     **\*\***      104
  **  establishment of localization**                             **+**   **\*\*\***   **−**     **\*\***    **344**
   cellular localization                                                               **−**    **\*\*\***      85
  * multi-organism process*                                       **−**    **\*\***    **+**    **\*\*\***   **142**
   pathogenesis                                                                        **+**     **\*\***       71
  biological regulation                                                                **−**     **\*\***      384
   regulation of biological process                                                    **−**     **\*\***      356
    regulation of metabolic process                                                    **−**     **\*\***      260
    regulation of cellular process                                                     **−**     **\*\***      332

Notation: Significance levels are at the 5% (\*), 1% (\*\*), or 0.1% (\*\*\*). Boldface indicates overrepresentation of SRV; italics indicates underrepresentation of SRV.

These findings suggest that forces driving either SRV or PS are not independent from the gene function, with distinct biases in their distribution among GO categories. Furthermore, with exception of organelles, there was a visible tendency to observe enrichment with SRV+ proteins in the same GO categories that were underrepresented with PS ([Tables 3](#pone-0095034-t003){ref-type="table"}--[5](#pone-0095034-t005){ref-type="table"}).

Information on biological pathways, in which a protein is involved, includes chemical reactions within a cell whose dependencies and dynamics are distinct from the notion of a biological process as classified by GO. Therefore, we also performed enrichment analyses for 18,041 human genes in KEGG with respect to their biological pathways ([Table 6](#pone-0095034-t006){ref-type="table"}). We classified a KEGG gene as being affected by PS (or SRV), if it was mapped to at least one PANDIT group that was classified as PS+ (or SRV+ respectively).

10.1371/journal.pone.0095034.t006

###### Over/under-representation of selective forces in KEGG Pathways.
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  KEGG Pathway                                                   *SRV*                PS                                             
  ---------------------------------------------------- ------------------------- ------------ ------------ --------- -------- ------ -----
  Metabolism                                                                                      1434       **−**     \*\*    1484  
  ** Carbohydrate Metabolism**                                   **+**              **\***      **300**                        313   
  **  Pentose phosphate pathway**                                **+**             **\*\***      **26**                         26   
   Pentose and glucuronate interconversions                                                        25         \+      \*\*\*    25   
  **  Fructose and mannose metabolism**                          **+**              **\***       **34**                         36   
   Ascorbate and aldarate metabolism                                                               26         \+      \*\*\*    26   
  **  Starch and sucrose metabolism**                            **+**             **\*\***      **54**       \+      \*\*\*    54   
  **  Inositol phosphate metabolism**                            **+**             **\*\***      **51**                         51   
  * Energy Metabolism*                                           **−**            **\*\*\***    **170**      **−**    \*\*\*   178   
  *  Oxidative phosphorylation*                                  **−**            **\*\*\***    **116**                        124   
  **  Nitrogen metabolism**                                      **+**              **\***       **24**                         24   
  Lipid Metabolism                                                                                317                          330   
  **  Androgen and estrogen metabolism**                          \+                  \*           44         \+      \*\*\*    46   
  *  alpha-Linolenic acid metabolism*                            **−**             **\*\***      **17**       \+        \*      17   
  ** Amino Acid Metabolism**                                     **+**              **\***      **295**                        303   
  **  Glycine, serine and threonine metabolism**                 **+**             **\*\***      **41**                         41   
  * Glycan Biosynthesis and Metabolism*                          **−**            **\*\*\***    **206**                        213   
   Glycosaminoglycan degradation                                                                   18         \+        \*      18   
  *  Glycosphingolipid biosynthesis - globoseries*               **−**            **\*\*\***     **14**                         14   
  *  Glycosphingolipid biosynthesis - ganglioseries*             **−**            **\*\*\***     **21**                         21   
  ** Metabolism of Cofactors and Vitamins**                       \+                  \*          190                          204   
  **  Retinol metabolism**                                        \+                  \*           56         \+      \*\*\*    65   
   Porphyrin and chlorophyll metabolism                                                            41         \+      \*\*\*    41   
  Xenobiotics Biodegradation and Metabolism                                                       156         \+      \*\*\*   160   
  **  Metabolism of xenobiotics by cytochrome P450**              \+                \*\*\*         66         \+      \*\*\*    70   
  **  Drug metabolism - cytochrome P450**                         \+                \*\*\*         68         \+      \*\*\*    72   
   Drug metabolism - other enzymes                                                                 52         \+      \*\*\*    52   
  **Genetic Information Processing**                              \+                  \*          560        **−**    \*\*\*   573   
  Translation                                                                                     143                          143   
  **  Aminoacyl-tRNA biosynthesis**                              **+**             **\*\***      **40**                         40   
  ** Folding, Sorting and Degradation**                           \+                  \*          257                          264   
  **  Ubiquitin mediated proteolysis**                            \+                  \*          125        **−**    \*\*\*   132   
  **  SNARE interactions in vesicular transport**                **+**              **\***       **37**                         37   
  *  Regulation of autophagy*                                    **−**               \*\*          34         \+      \*\*\*    34   
  **Environmental Information Processing**                       **+**            **\*\*\***    **1434**      \+      \*\*\*   1480  
  ** Membrane Transport**                                        **+**            **\*\*\***     **42**                         42   
  **  ABC transporters**                                         **+**            **\*\*\***     **42**                         42   
  ** Signal Transduction**                                       **+**            **\*\*\***    **849**                        892   
  **  MAPK signaling pathway**                                   **+**            **\*\*\***    **265**                        272   
  **  ErbB signaling pathway**                                   **+**            **\*\*\***     **85**                         85   
  **  Calcium signaling pathway**                                **+**            **\*\*\***    **170**                        181   
  **  Phosphatidylinositol signaling system**                    **+**            **\*\*\***     **69**                         75   
  **  Hedgehog signaling pathway**                               **+**              **\***       **56**                         57   
  *  Jak-STAT signaling pathway*                                 **−**            **\*\*\***    **126**                        145   
  ** Signaling Molecules and Interaction**                       **+**            **\*\*\***    **729**       \+      \*\*\*   750   
  **  Neuroactive ligand-receptor interaction**                  **+**             **\*\***     **292**       \+      \*\*\*   295   
  **  ECM-receptor interaction**                                 **+**              **\***       **84**       \+      \*\*\*    84   
  **  Cell adhesion molecules (CAMs)**                           **+**            **\*\*\***    **128**       \+      \*\*\*   130   
  **Cellular Processes**                                         **+**            **\*\*\***    **1774**      \+      \*\*\*   1837  
  ** Cell Motility**                                             **+**            **\*\*\***    **201**                        213   
  **  Regulation of actin cytoskeleton**                         **+**            **\*\*\***    **201**                        213   
  Cell Growth and Death                                                                           210        **−**      \*     225   
  ** Cell Communication**                                        **+**            **\*\*\***    **400**       \+      \*\*\*   413   
  **  Focal adhesion**                                           **+**            **\*\*\***    **193**                        201   
  **  Adherens junction**                                        **+**             **\*\***      **77**                         78   
  **  Tight junction**                                           **+**            **\*\*\***    **116**       \+      \*\*\*   128   
  **  Gap junction**                                             **+**            **\*\*\***     **96**                         96   
  ** Endocrine System**                                          **+**              **\***      **369**                        381   
  **  Insulin signaling pathway**                                **+**              **\***      **129**                        136   
  **  Melanogenesis**                                            **+**            **\*\*\***     **96**                        102   
   Adipocytokine signaling pathway                                                                 61        **−**      \*      66   
  Immune System                                                                                   519         \+      \*\*\*   547   
  *  Antigen processing and presentation*                        **−**              **\***       **82**       \+      \*\*\*    86   
   Natural killer cell mediated cytotoxicity                                                      132         \+      \*\*\*   139   
  **  Leukocyte transendothelial migration**                     **+**            **\*\*\***    **109**       \+      \*\*\*   117   
  ** Sensory System**                                            **+**            **\*\*\***    **416**       \+      \*\*\*   429   
  **  Olfactory transduction**                                   **+**            **\*\*\***    **370**       \+      \*\*\*   381   
  **  Taste transduction**                                       **+**              **\***       **51**       \+      \*\*\*    53   
  ** Development**                                               **+**            **\*\*\***    **124**                        129   
  **  Axon guidance**                                            **+**            **\*\*\***    **124**                        129   
  **Human Diseases**                                             **+**            **\*\*\***    **983**                        1025  
  ** Cancers**                                                   **+**            **\*\*\***    **365**                        378   
  **  Pathways in cancer**                                       **+**            **\*\*\***    **305**                        312   
  **  Colorectal cancer**                                        **+**            **\*\*\***     **83**                         83   
  **  Endometrial cancer**                                       **+**             **\*\***      **50**                         50   
  **  Basal cell carcinoma**                                     **+**            **\*\*\***     **54**                         55   
  **  Melanoma**                                                 **+**            **\*\*\***     **68**                         69   
  ** Immune Disorders**                                          **+**             **\*\***     **225**       \+        \*     229   
   Asthma                                                                                          30         \+      \*\*\*    30   
   Autoimmune thyroid disease                                                                      53         \+      \*\*\*    53   
  **  Systemic lupus erythematosus**                             **+**            **\*\*\***    **143**                        143   
   Allograft rejection                                                                             38         \+      \*\*\*    38   
   Graft-versus-host disease                                                                       42         \+      \*\*\*    42   
  Neurodegenerative Diseases                                                                      275                          297   
  *  Alzheimer's disease*                                        **−**             **\*\***     **145**                        162   
  *  Parkinson's disease*                                        **−**            **\*\*\***    **116**                        124   
  *  Huntington's disease*                                       **−**             **\*\***     **162**                        172   
  ** Metabolic Disorders**                                       **+**            **\*\*\***     **96**       \+       \*\*    104   
  **  Type II diabetes mellitus**                                **+**            **\*\*\***     **42**                         43   
   Type I diabetes mellitus                                                                        42         \+      \*\*\*    44   
                                                        **Infectious Diseases**     **+**      **\*\*\***   **147**                   149
  **  Pathogenic Escherichia coli infection**                    **+**             **\*\***      **53**                         53   

Notation: Significance levels are at the 5% (\*), 1% (\*\*), or 0.1% (\*\*\*). Boldface indicates overrepresentation of SRV; italics indicates underrepresentation of SRV.

SRV+ genes were found to be enriched for a wide variety of functions related to metabolic pathways, particularly in carbohydrate and amino acid metabolism, metabolism of cofactors and vitamins, metabolism of xenobiotics by cytochrome and drug metabolism - cytochrome. This finding is consistent with our observations about metabolic processes based on GO. However, the analyses of KEGG pathways also revealed certain metabolic pathways where SRV+ genes were underrepresented. This result might be due to the fact that gene ontologies are not equivalent to pathways: pathways could involve genes that are not directly relevant to the metabolic process, but are included because of the pathway inter-process dependencies and specific dynamics. Additionally, this may be also due to the fact that KEGG analysis is done only on human genes, unlike GO.

Our analyses of GO terms identified that metabolic processes were generally conserved. Studies of positive selection on the protein level [@pone.0095034-ArisBrosou1], [@pone.0095034-Kosiol1], [@pone.0095034-Nielsen1] mainly refer to metabolic processes, but not to metabolic pathways. The differences in our results from KEGG and GO for positive selection might be due to the way of classification of KEGG genes as PS+ (having found at least one PANDIT data product of that gene as positively selected). Namely, a gene is annotated for all the functions and processes of its products, so it may happen that positive selection in a gene is due to positive selection only in a certain protein domain while the signal for positive selection will be tracked for all the functions and processes that the gene is annotated, i.e. all the pathway annotations of its products.

Further, we found an overrepresentation of SRV among the genes participating in some genetic and environmental information processing pathways. We observed underrepresentation of PS among the genes involved in genetic information processing pathways, but overrepresentation of PS among the genes involved in environmental information processing pathways.

Among the cellular processes, cell motility and communication, endocrine and sensory system, and developmental pathways were found to be overrepresented with SRV+ genes. Categories overrepresented with PS+ genes included cell communication and immune and sensory system pathways. These findings are generally consistent with our previous findings for SRV in cellular processes using GO annotations. However, note that the hierarchical structure of cellular processes in KEGG and GO databases is different. For example, GO terms for immune system processes are not "descendants" of terms for cellular processes, while in KEGG cellular process pathways include immune, nervous and sensory system pathways. Therefore, a simple comparison of trends for cellular processes in KEGG and GO is not possible without looking into the finer sub-categories. If the immune, nervous and sensory system pathways were excluded from the KEGG cellular process pathways, then overrepresentation of PS+ in the cellular processes group could not be observed.

Generally, significant overrepresentation of SRV was found among genes involved in human diseases. SRV+ genes were enriched in cancer related pathways ([Figure 2](#pone-0095034-g002){ref-type="fig"}). Very strong overrepresentation of SRV+ genes was also found in metabolic disorders (type II diabetes mellitus) and immune disorders (systemic lupus erythematosus). Underrepresentation of genes with SRV was detected among genes involved in neurodegenerative disease pathways. Immune and metabolic disorders pathways exhibited an overrepresentation of PS+ genes.

![Hierarchical clustering of human disease and environmental information processing pathways in respect to the SRV+ genes that are shared between the pathways.\
The bars next to the pathways denote the number of SRV+ genes (red) and SRV- genes (green) in the corresponding pathways. Cancer related pathways are marked in blue; metabolic disease pathways are in purple. Note that ABC transporters and Type II diabetes mellitus pathways are exclusively composed of SRV+ genes.](pone.0095034.g002){#pone-0095034-g002}

Site-to-site SRV and Gene Expression Patterns {#s3c}
---------------------------------------------

To test if SRV+ genes are over/underrepresented among the genes expressed in different human tissues, we analyzed gene expression data of 8,175 human genes from HumanProteinpedia (HPRD) expressed in 57 healthy and 20 disease tissues, which were uniquely mapped to KEGG genes. Significant evidence of overrepresentation of SRV+ genes was found among genes expressed in brain, cerebrospinal fluid, liver and pancreatic juice. Among the genes expressed in blood plasma there was an overrepresentation of PS+ genes, while conserved genes were overrepresented among the genes expressed in brain, ovary and stem cell. Indeed, in a previous study genes expressed in the brain were among the most conserved genes with the least evidence for PS [@pone.0095034-Kosiol1]. Note that in that study blood plasma was not analyzed as a separate tissue.

Further, we tested for possible relation between gene expression breadth, measured by the number of expression tissues, and the SRV/PS forces. Several studies report that broadly expressed genes evolve more slowly than tissue specific genes (eg. [@pone.0095034-Zhang1], [@pone.0095034-Park1]). The power for detecting such correlation is very limited with the HPRD data, as it is skewed towards low expression breaths ([Figure S5](#pone.0095034.s005){ref-type="supplementary-material"}). Therefore, to analyze the correlation between gene expression breadth and SRV/PS we used data from [@pone.0095034-Necsulea1] that mapped Ensembl gene IDs to gene expression breadth values estimated from Gene Atlas microarray, EST and SAGE experiments for human tissues. Our analyses revealed negative correlation between expression breadth and the average CV of *d~S~* (*ρ* = −0.81, P = 0.02) and the average *ω*-ratio (*ρ* = −0.79, P = 0.02) using Gene Atlas microarray data ([Figure S6](#pone.0095034.s006){ref-type="supplementary-material"}). Similar results were obtained using SAGE and EST data ([Figure S7](#pone.0095034.s007){ref-type="supplementary-material"}--[S8](#pone.0095034.s008){ref-type="supplementary-material"}).

Additionally, we used expression measurements in 86 tissues from Gene Atlas Affymetrix U133A microarray. 4,095 proteins that were classified into SRV+/− and PS+/− groups were mapped to the microarray probes. We examined mRNA expression levels of SRV+ and SRV− genes and observed no difference. However, genes with extreme SRV (CV ≥ 0.8), showed increased expression levels in nearly all tissues. There were 243 such genes and we refer to them as SRV~EXT~ genes. We compared the distribution of the expression levels of the SRV~EXT~ gene group to the distribution of the expression levels of the SRV− genes. The differences were the most pronounced in several neural tissues: hypothalamus, medulla oblongata, occipital lobe, pineal day, pineal night, prefrontal cortex, spinal cord, amygdala, caudate nucleus, cingulate cortex, fetal brain, whole brain. [Figure 3A](#pone-0095034-g003){ref-type="fig"} shows the differences in the distribution of the expression levels in several tissues. The observed differences remained when we compared the distribution of the expression levels of the SRV~EXT~ genes to the distribution of the expression levels of the SRV− genes including the subgroup of SRV+ genes where CV of *d~S~* was \<0.8. Consistently with the study of Kosiol et al. [@pone.0095034-Kosiol1], we observed decreased expression levels of PS+ genes in all tissues ([Figure 3B](#pone-0095034-g003){ref-type="fig"}). Using this gene expression dataset we observed significant overrepresentation of SRV among the genes expressed in small intestine, pancreas, tongue and several brain tissues. With the Gene Atlas Affymetrix microarray data cerebrospinal fluid and pancreatic juice were not experimentally tested as separate tissues.

![Distribution of the expression levels in A) SRV− genes (blue) and SRV~EXT~ genes (red) and B) PS− genes (green) and PS+ genes (purple) for different tissues.\
SRV~EXT~ genes show higher expression levels compared to SRV− genes; PS+ genes show reduced expression levels compared to PS− genes.](pone.0095034.g003){#pone-0095034-g003}

Discussion {#s4}
==========

Large-scale scans for adaptively evolving genes have provided valuable insights into the patterns of positive selection in protein-coding genes, but have left many important questions unanswered. In coding sequences selection may also operate on synonymous sites, contributing to significant variability patterns with respect to the conservation of the synonymous substitution rate and codon usage.

Our analyses of protein families and domains revealed that the site-to-site SRV is a ubiquitous phenomenon affecting over a third of homologous protein domains and families. Strikingly, our study suggests that variation in synonymous rates is more likely in genes that are conserved and are least likely to undergo adaptation at the protein level. Proteins with significant SRV are involved in complex functions, exhibit stronger codon bias and tRNA reusage, have larger number of interactions and participate in forming a larger number of structural complexes. In contrast, we found that genes affected by positive selection tend to have weaker codon bias and fewer interaction partners and form fewer protein complexes. This is consistent with the previous findings: several studies found that the connectivity of proteins in the network is negatively correlated with their rate of evolution [@pone.0095034-ArisBrosou1], [@pone.0095034-Fraser1], [@pone.0095034-Yook1].

It has been suggested that proteins with more interactions evolve more slowly because different interactions typically depend on different sites, and so a greater part of the protein is under strong functional constraint [@pone.0095034-Fraser1]. At sites important for interaction between proteins, evolutionary changes may occur largely by co-evolution, in which substitutions in one protein result in selection pressure for reciprocal changes in interacting partners. While we found weak negative correlation between the strength of positive selection and the number of structural complexes, this was not found significant in [@pone.0095034-ArisBrosou1], most likely because at that time the number of structural complexes in Pfam was underestimated (with fewer structures known) and due to smaller size of PANDIT. However, it was shown that families and protein domains that form at least one structure tend to be more conserved. This could suggest that selection acts on all members of the complex, irrespective of the number of complexes formed by each member of the complex [@pone.0095034-ArisBrosou1].

Another surprising finding of our study is that positive selection on the protein tends to be in an antagonistic relationship with forces responsible for the SRV − a trend seen in most of our analyses of gene features (codon/tRNA bias, expression, function). For example, protein domains (very stable protein units optimized through deep evolutionary times) evolve slowly compared to protein families (which often evolve under changing evolutionary constraints after gene duplications). Here we found that domains were less likely to undergo positive selection on the protein, but more likely to have SRV. Possibly for domains, protein "building blocks" that are reused in different protein architectures, the exploration of the synonymous mutational landscape is the best way of fine-tuning the already well-optimized amino acid sequence. In contrast, protein families were found to be more likely to undergo positive selection on the protein, but less likely to have significant SRV. Gene ontologies enriched with SRV were often underrepresented with PS.

This may suggest that site-to-site variation of synonymous rates and codon bias are more likely to produce more subtle effects on protein transcription and translation, and so the SRV might be one of the mechanisms of adaptation in the proteins that evolve slowly. Indeed, in very conserved proteins most (if not all) nonsynonymous mutations would result in a dysfunctional protein product and would be selected against. The exploration of mutational landscape is then possible mostly through synonymous mutations. For example, depending on the position in a sequence the use of rare (or optimal) codons may slow down (or speed up) the translation, which can be crucial for correct protein folding [@pone.0095034-Komar1]. In another example, differences in mRNA stability were attributed to synonymous mutations in the conserved gene *lady bird early* (lbe) from the homeobox cluster of *Drosophila melanogaster* [@pone.0095034-Balakirev1]. This example is consistent with our observations: on lbe balancing selection on synonymous sites acts at the background of strict purifying selection on the protein.

Crucially, the understanding of protein function requires a detailed analysis of sequence-structure-function trinity. Here we focused on sequences with SRV, a phenomenon that may affect protein folding, abundance, degradation and function - through the regulation of translational rate or mRNA stability. In our study, proteins found in the cell interior (with exception of organelles) tended to have more SRV, while it was observed less frequently in proteins located in the extracellular region. Again, this pattern is opposite to the well-known localization pattern for proteins whose protein encoding sequences are under positive selection on the protein level. Furthermore, proteins involved in metabolic and cellular processes, transporter activities and binding exhibited significant excess of SRV.

Several pathways are especially rich in genes with SRV, suggesting that selective forces on synonymous sites may frequently act directly on whole protein complexes or pathways. This can be seen from our clustering of SRV genes by KEGG terms, where several disease pathways and related environmental information processing pathways frequently share many genes with SRV ([Figure 2](#pone-0095034-g002){ref-type="fig"}). This is supported by recent literature reporting known associations of synonymous mutations with \>40 human diseases [@pone.0095034-Sauna1].

Alternatively, some studies suggested that adaptive changes in one protein may sometimes have a cascade effect, leading to changes in other genes that bring a system back into the equilibrium [@pone.0095034-Presgraves1]. Further investigation in this respect is needed in order to analyze the effects of the synonymous changes along the pathway and to reveal the reasons for overrepresentation of genes with SRV in certain pathways.

Genes expressed in certain tissues (brain, cerebrospinal fluid, liver, pancreatic juice) showed excess of SRV. Moreover, genes with extreme SRV had increased expression levels in most of the human tissues, especially in brain tissues. This may indicate that codon bias towards optimal codons, which correlates with gene expression, may not affect all sites, but is often a site-specific phenomenon. Indeed, as mentioned above, variation in usage of optimal vs rare codons could act as a mechanism for regulating the speed of translation along the sequence, consistent with the co-translational folding hypothesis. Some recent studies suggested that site-specific codon preferences may be better explained by pressures for translational accuracy [@pone.0095034-Ingolia1]--[@pone.0095034-Li1] rather than speed of translation, and the impact of rare codon clusters on ribosomal occupancy has been recently questioned based on ribosomal footprinting in yeast [@pone.0095034-Charneski1]. This highlights the complexity of the relationship between selection on synonymous sites, biochemical properties of the transcript, protein production and the eventual function of protein product, necessitating further studies in this direction.

Recent reports show that synonymous SNPs (synSNPs) can be associated with disease phenotype, causing disease or be responsible for differences in individual responses to drug treatment. If a haplotype with a synSNP has higher fitness, it will increase in frequency due to selection. Growing number of diseases are associated with synonymous polymorphisms, such as several types of cancers, hyperinsulinism of infancy, diabetes, and prion-related conditions, to name a few [@pone.0095034-Sauna1], [@pone.0095034-Komar1], [@pone.0095034-Shah1], [@pone.0095034-Komar2], [@pone.0095034-Komar3], [@pone.0095034-Sauna3], [@pone.0095034-Kelly1]. Indeed, in our data we observed high SRV in genes associated with diabetes, lupus and various cancers. We found significant SRV in several human genes where synSNPs have been documented to lead or contribute to a disease [@pone.0095034-Sauna2], among such examples are: the CHRNE gene, where a synSNP can directly cause a Myastenic syndrome (muscle disease); the FGFR2 gene, where a synSNP is a direct cause of a Crouzon syndrome (bone disease); the tumor suppressor protein p53, where synonymous polymorphisms are associated with overall tumor susceptibility, pathology and prognosis; the EGFR gene, where synSNPs may be a potential predictor for clinical outcome in advanced Non-Small-Cell Lung carcinoma; the PAH gene, where synSNPs can lead to Phenylketonuria; the CHRNA4 gene, where synSNPs are associated with Alzheimer's disease; in the three genes PADI2, SYNGR1 and DRD2 associated with schizophrenia. Interestingly, we also detected significant SRV in the MDR-1 gene − the first known case where the effect of a synonymous change on protein folding was demonstrated in vivo (discussed in the introduction; [@pone.0095034-KimchiSarfaty1], [@pone.0095034-Tsai1]). Our analyses identified overrepresentation of SRV in metabolizing enzymes and transporters, which are subject to many pharmacogenetics studies because they determine the disposition, safety and efficacy of small molecule drugs [@pone.0095034-Sauna1].

Overall, the SRV statistic carries a real signal, identifying important genes including those associated to human disease. However, like for any automated large-scale study, the conclusions should not be overgeneralized and taken with caution: hidden effects such as errors in annotation and reduced power of LRTs for small or too divergent alignments may have contributed to the overall signal (indeed in our data correlation was found with number of taxa and divergence, although weak and clearly non-linear (see [Figure S9](#pone.0095034.s009){ref-type="supplementary-material"})). The possibility that size/divergence of alignments may cause variation in power of LRT for positive selection (which are methodologically quite similar to the LRT for SRV that we used here) has been thoroughly studied in [@pone.0095034-Anisimova2] using computer simulations. The study showed that for small alignments and too low/deep divergences the LRT remained accurate but had decreased power. To check that this did not bias our results, we repeated all analyzes by removing small alignments (in different combinations) with and without a threshold of ≥0.3 on the CV of SRV. We could confirm the reported trends in all cases.

Whole-genome investigations on a fixed number of lineages would help to reduce some of the above-mentioned effects. Further, to detect positions affected by site-specific selection on synonymous changes with sufficient confidence, better models and tests need to be developed, taking into account site-to-site codon variability. Better understanding of site-specific synonymous variability promises to become an important contribution to revising the central molecular biology concepts, to improving structural prediction, and to our understanding of genetic diseases with respect to potential effects of synonymous mutations.

Supporting Information {#s5}
======================

###### 

**Histogram of PANDIT data sets divergence.** The divergence (expected substitutions per amino acid site per branch) was calculated as AA tree length divided by 2\*T-3, where T is the number of sequences in the PANDIT data set. The AA tree length and the number of sequences in the each data set were extracted from PANDIT.

(TIF)

###### 

Click here for additional data file.

###### 

**Bootstrap distributions of the differences in mean values of A) Codon Bias Indices (CBI) and B) Effective Number of Codons (ENC) between protein groups showing evidence for site-to-site variation in synonymous rates (SRV+) and those failing to show such evidence (SRV−), and protein groups showing evidence for positive selection (PS+) and those failing to show such evidence (PS−).** The differences are significant, since 95% of the histogram area does not include the zero value for all histograms.

(TIF)

###### 

Click here for additional data file.

###### 

**Bootstrap distributions of the differences in A) mean GC content values and B) GC3 content values between PANDIT members showing evidence for site-to-site variation in synonymous rates (SRV+) and those failing to show such evidence (SRV−), and PANDIT members showing evidence for positive selection (PS+) and those failing to show such evidence (PS−).** All the differences are significant, since 95% of the histogram area does not include the zero value for all histograms.

(TIF)

###### 

Click here for additional data file.

###### 

**Distributions of data in GO terms.**

(TIF)

###### 

Click here for additional data file.

###### 

**Expression breadth histogram of genes in HumanProteinpedia Database.**

(TIF)

###### 

Click here for additional data file.

###### 

**Correlation between gene expression breadth (number of tissues of gene expression) calculated from human Gene Atlas microarray data and A) average CV of synonymous rates and B) average ω ratio, calculated for each bin of 10 tissues.** The Gene Atlas microarray expression breadth values were taken from Necsulea et al. (2009).

(TIF)

###### 

Click here for additional data file.

###### 

**Correlation between gene expression breadth (number of tissues of gene expression) calculated from human SAGE data and A) average CV of synonymous rates and B) average ω ratio.** The SAGE gene expression breadth values were taken from Necsulea et al. (2009).

(TIF)

###### 

Click here for additional data file.

###### 

**Correlation between gene expression breadth (number of tissues of gene expression) calculated from human EST data and A) average CV of synonymous rates and B) average ω ratio.** The EST gene expression breadth values were taken from Necsulea et al. (2009).

(TIF)

###### 

Click here for additional data file.

###### 

**Correlation between individual variables (stated in the diagonal).** The numbers in the upper-diagonal plots denote the correlation coefficients for the corresponding pairs of variables. The lower-diagonal plots represent plots of the corresponding data.

(TIF)

###### 

Click here for additional data file.

###### 

**PFAM protein groups with extreme site-to-site heterogeneity of synonymous rates (coefficient of variation (CV) ≥1).**

(XLS)

###### 

Click here for additional data file.

###### 

**Clans that are exclusively composed of PFAM groups identified as having site-to-site heterogeneity of synonymous rates (SRV+).**

(XLS)

###### 

Click here for additional data file.

###### 

**Strength of correlation between codon bias, tRNA reusage and nucleotide composition and SRV/PS.** Note that negative correlation with ENC indicates positive correlation to codon bias, since, unlike CBI, smaller ENC indicates stronger codon bias.

(XLS)

###### 

Click here for additional data file.
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